Shanghai Henlius Biotech, Inc. (02696.HK)

Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. The company is headquartered in Shanghai, Shanghai and currently employs 3,537 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The firm mainly operates its businesses in the domestic and overseas markets.